These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27456883)

  • 1. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
    Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
    Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Prosperini L; Borriello G; De Giglio L; Leonardi L; Barletta V; Pozzilli C
    BMC Neurol; 2011 Feb; 11():26. PubMed ID: 21352517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
    Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
    Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing response to interferon-β in a multicenter dataset of patients with MS.
    Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
    Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
    Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
    Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
    Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon-beta response in multiple sclerosis associated with pre-treatment disability].
    Fernandez-Fernandez O; Fernandez-Sanchez VE; Mayorga C; Guerrero-Fernandez M; Leon A; Tamayo-Toledo JA; Alonso A; Romero F; Leyva L; Luque G; de Ramon E
    Rev Neurol; 2006 Sep 16-30; 43(6):322-9. PubMed ID: 16981161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of the location of multiple sclerosis relapse.
    Deen S; Bacchetti P; High A; Waubant E
    J Neurol Neurosurg Psychiatry; 2008 Oct; 79(10):1190-3. PubMed ID: 18223021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
    Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
    Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group.
    Neurology; 1996 Oct; 47(4):889-94. PubMed ID: 8857714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.